Literature DB >> 26135834

Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity.

Chao Yu1, Min Wang2, Meiyuan Chen1, Yang Huang1, Jianxin Jiang1.   

Abstract

The present study investigated the role of microRNA (miR)‑138‑5p in regulating carcinoma migration and sensitivity to chemotherapy in pancreatic cancer. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to assess the expression levels of miR‑138‑5p in pancreatic cancer cell lines and primary carcinoma tissues from human patients. A lentiviral vector, containing miR‑138‑5p mimics (lv‑miR‑138‑m) or miR‑138‑5p inhibitor (lv‑miR‑138‑i), was used to either upregulate or downregulate the expression levels of miR‑138‑5p in PANC‑1 cells, respectively. The effects of miR‑138‑3p regulation on pancreatic cancer cell migration and sensitivity to chemotherapy were examined. The predicted targeting of miR‑138‑5p on vimentin (VIM) was assessed by western blotting in PANC‑1 cells. VIM was subsequently downregulated using small interfering (si)RNA to determine its effect on miR‑138‑5p‑modulated pancreatic cancer cell development. The expression levels of miR‑138‑5p were downregulated in pancreatic cancer cell lines and primary carcinoma tissues. In PANC‑1 cells, lentivirus-mediated upregulation of miR‑138‑5p inhibited cancer cell migration and increased cell chemosensitivity to 5‑fluorouracil (5‑FU). By contrast, downregulation of miR‑138‑5p promoted cancer cell migration and decreased cell chemosensitivity to 5‑FU. A luciferase assay revealed that VIM was a direct target of miR‑138‑5p. Western blotting demonstrated that VIM was downregulated upon the upregulation of miR‑138‑5p in PANC‑1 cells. siRNA‑mediated downregulation of VIM inhibited pancreatic cancer cell migration in the control and miR‑138‑5p downregulated PANC‑1 cells. The present study demonstrated that miR‑138‑5p is important in regulating pancreatic cancer development, possibly through targeting VIM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135834     DOI: 10.3892/mmr.2015.4031

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

Review 1.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

2.  MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance.

Authors:  Weifeng Xu; Beibei Chen; Dianshan Ke; Xiaobing Chen
Journal:  Cancer Cell Int       Date:  2020-10-01       Impact factor: 5.722

3.  MicroRNA-138 inhibits tumor growth and enhances chemosensitivity in human cervical cancer by targeting H2AX.

Authors:  Min Yuan; Shuting Zhao; Rui Chen; Guozeng Wang; Yachun Bie; Qianyu Wu; Jingxin Cheng
Journal:  Exp Ther Med       Date:  2019-11-22       Impact factor: 2.447

4.  Decreased Expression of miR-138-5p by lncRNA H19 in Cervical Cancer Promotes Tumor Proliferation.

Authors:  Lei Ou; Dazhong Wang; Han Zhang; Qian Yu; Fangfang Hua
Journal:  Oncol Res       Date:  2017-08-10       Impact factor: 5.574

Review 5.  MiRNA-mediated EMT and CSCs in cancer chemoresistance.

Authors:  Bing Dong; Shiyu Li; Shuangli Zhu; Ming Yi; Suxia Luo; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-02-12

6.  Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.

Authors:  Taohui Zeng; Lin Luo; Yuye Huang; Xiaoli Ye; Jinhai Lin
Journal:  Biomed Res Int       Date:  2021-03-06       Impact factor: 3.411

Review 7.  Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer.

Authors:  Seung Wan Son; Mun Gyu Song; Ba Da Yun; Jong Kook Park
Journal:  Biomedicines       Date:  2021-03-07

8.  Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML.

Authors:  Dong-Hu Yu; Chen Chen; Xiao-Ping Liu; Jie Yao; Sheng Li; Xiao-Lan Ruan
Journal:  Front Cell Dev Biol       Date:  2021-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.